,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': 'Application received from a supplier.', 'fs': 'Application received from a supplier.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2015', 'fs': 'Aug 2015', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtqUAG'}, 'Id': 'a0P2P000004DKtqUAG', 'Event_Date__c': '2015-08-20', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Summary__c': 'Application received from a supplier.', 'Formatted_Date__c': 'Aug 2015', 'Status_History__c': 'a132P000000AqyrQAC'}, 'change': None}, {'Summary': {'s': 'Application from supplier received', 'fs': 'Application from supplier received', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2017', 'fs': 'Jul 2017', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtuUAG'}, 'Id': 'a0P2P000004DKtuUAG', 'Event_Date__c': '2017-07-10', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Summary__c': 'Application from supplier received', 'Formatted_Date__c': 'Jul 2017', 'Status_History__c': 'a132P000000ArJEQA0'}, 'change': None}]",Aug 2015,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'The Subcommittee noted that pimecrolimus cream 1% is not fully subsidised in the Pharmaceutical Schedule and, as it does not have a niche use in hospitals, recommended that it not be included in the initial version of the Hospital Medicines List (Section H).', 'fs': 'The Subcommittee noted that pimecrolimus cream 1% is not fully subsidised in the Pharmaceutical Schedule and, as it does not have a niche use in hospitals, recommended that it not be included in the initial version of the Hospital Medicines List (Section H).', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Not recommended for inclusion (HML)', 'fs': 'Not recommended for inclusion (HML)', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatologicals-group-minutes-2012-11.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatologicals-group-minutes-2012-11.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2011', 'fs': 'Oct 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 4 October 2011.', 'fs': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 4 October 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtlUAG'}, 'Id': 'a0P2P000004DKtlUAG', 'Event_Date__c': '2011-10-04', 'Event_Description__c': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 4 October 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatologicals-group-minutes-2012-11.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'Outcome__c': 'Not recommended for inclusion (HML)', 'Summary__c': 'The Subcommittee noted that pimecrolimus cream 1% is not fully subsidised in the Pharmaceutical Schedule and, as it does not have a niche use in hospitals, recommended that it not be included in the initial version of the Hospital Medicines List (Section H).', 'Formatted_Date__c': 'Oct 2011', 'Status_History__c': 'a132P000000ApttQAC'}, 'change': None}, {'Summary': {'s': '&#39;The Subcommittee noted that the Hospital Pharmaceuticals Subcommittee had recommended against the inclusion of pimecrolimus cream in a national PML. Members noted that tacrolimus cream is preferred to pimecrolimus, and considered that this should only be included in a national PML if it was subsidised in the community.&#39;', 'fs': '&#39;The Subcommittee noted that the Hospital Pharmaceuticals Subcommittee had recommended against the inclusion of pimecrolimus cream in a national PML. Members noted that tacrolimus cream is preferred to pimecrolimus, and considered that this should only be included in a national PML if it was subsidised in the community.&#39;', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Not recommended for inclusion (HML)', 'fs': 'Not recommended for inclusion (HML)', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2012-05.pdf"" target=""_blank"">Dermatology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2012-05.pdf"" target=""_blank"">Dermatology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2012', 'fs': 'May 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Dermatology Subcommittee at meeting Tuesday 15 May 2012.', 'fs': 'Clinical advice received from Dermatology Subcommittee at meeting Tuesday 15 May 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtmUAG'}, 'Id': 'a0P2P000004DKtmUAG', 'Event_Date__c': '2012-05-15', 'Event_Description__c': 'Clinical advice received from Dermatology Subcommittee at meeting Tuesday 15 May 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2012-05.pdf"" target=""_blank"">Dermatology Subcommittee minutes</a>', 'Outcome__c': 'Not recommended for inclusion (HML)', 'Summary__c': '&#39;The Subcommittee noted that the Hospital Pharmaceuticals Subcommittee had recommended against the inclusion of pimecrolimus cream in a national PML. Members noted that tacrolimus cream is preferred to pimecrolimus, and considered that this should only be included in a national PML if it was subsidised in the community.&#39;', 'Formatted_Date__c': 'May 2012', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000Aq2XQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Not recommended for inclusion (HML)', 'fs': 'Not recommended for inclusion (HML)', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2012', 'fs': 'Nov 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 November 2012.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 November 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtnUAG'}, 'Id': 'a0P2P000004DKtnUAG', 'Event_Date__c': '2012-11-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 November 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Not recommended for inclusion (HML)', 'Formatted_Date__c': 'Nov 2012', 'Status_History__c': 'a132P000000AqCQQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2015', 'fs': 'Nov 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtrUAG'}, 'Id': 'a0P2P000004DKtrUAG', 'Event_Date__c': '2015-11-30', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2015', 'Status_History__c': 'a132P000000Ar2pQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">Dermatology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">Dermatology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2015', 'fs': 'Nov 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Dermatology Subcommittee at meeting Monday 30 November 2015.', 'fs': 'Clinical advice received from Dermatology Subcommittee at meeting Monday 30 November 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtsUAG'}, 'Id': 'a0P2P000004DKtsUAG', 'Event_Date__c': '2015-11-30', 'Event_Description__c': 'Clinical advice received from Dermatology Subcommittee at meeting Monday 30 November 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2015-11.pdf"" target=""_blank"">Dermatology Subcommittee minutes</a>', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'Nov 2015', 'Status_History__c': 'a132P000000Ar2tQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2015', 'fs': 'Nov 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKttUAG'}, 'Id': 'a0P2P000004DKttUAG', 'Event_Date__c': '2015-11-30', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2015', 'Status_History__c': 'a132P000000Ar2vQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Cost Neutral', 'fs': 'Cost Neutral', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2017-11.pdf"" target=""_blank"">Dermatology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2017-11.pdf"" target=""_blank"">Dermatology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2017', 'fs': 'Oct 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Dermatology Subcommittee at meeting Friday 20 October 2017.', 'fs': 'Clinical advice received from Dermatology Subcommittee at meeting Friday 20 October 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtvUAG'}, 'Id': 'a0P2P000004DKtvUAG', 'Event_Date__c': '2017-10-20', 'Event_Description__c': 'Clinical advice received from Dermatology Subcommittee at meeting Friday 20 October 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-dermatology-subcommittee-minutes-2017-11.pdf"" target=""_blank"">Dermatology Subcommittee minutes</a>', 'Outcome__c': 'Cost Neutral', 'Formatted_Date__c': 'Oct 2017', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000ArLyQAK'}, 'change': None}, {'Summary': {'s': 'PTAC 2018 02 The Committee noted that the Dermatology Subcommittee recommended pimecrolimus 1% ointment be listed, either for all patients with atopic dermatitis and without a Special Authority only if cost-neutral to hydrocortisone acetate 1% cream, or only for atopic dermatitis on eyelids and subject to Special Authority criteria, and   a maximum of 15 gm per 6 months. The Committee considered that there was a risk of indication creep leading to larger amounts of this product being used.', 'fs': 'PTAC 2018 02 The Committee noted that the Dermatology Subcommittee recommended pimecrolimus 1% ointment be listed, either for all patients with atopic dermatitis and without a Special Authority only if cost-neutral to hydrocortisone acetate 1% cream, or only for atopic dermatitis on eyelids and subject to Special Authority criteria, and   a maximum of 15 gm per 6 months. The Committee considered that there was a risk of indication creep leading to larger amounts of this product being used.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Cost Neutral', 'fs': 'Cost Neutral', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtwUAG'}, 'Id': 'a0P2P000004DKtwUAG', 'Event_Date__c': '2018-02-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Cost Neutral', 'Summary__c': 'PTAC 2018 02 The Committee noted that the Dermatology Subcommittee recommended pimecrolimus 1% ointment be listed, either for all patients with atopic dermatitis and without a Special Authority only if cost-neutral to hydrocortisone acetate 1% cream, or only for atopic dermatitis on eyelids and subject to Special Authority criteria, and   a maximum of 15 gm per 6 months. The Committee considered that there was a risk of indication creep leading to larger amounts of this product being used.', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArPoQAK'}, 'change': None}]",Oct 2011,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,,,False,False
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2018', 'fs': 'Jun 2018', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtxUAG'}, 'Id': 'a0P2P000004DKtxUAG', 'Event_Date__c': '2018-06-06', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2018', 'Status_History__c': 'a132P000000ArTjQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtyUAG'}, 'Id': 'a0P2P000004DKtyUAG', 'Event_Date__c': '2018-09-04', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArWuQAK'}, 'change': None}]",Jun 2018,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2012', 'fs': 'Nov 2012', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtoUAG'}, 'Id': 'a0P2P000004DKtoUAG', 'Event_Date__c': '2012-11-19', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'Nov 2012', 'Status_History__c': 'a132P000000AqEdQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://www.pharmac.govt.nz/news/consultation-2020-08-11-calcineurin-inhibitor/"" target=""_blank"">Consultation letter</a></p>', 'fs': '<p><a href=""https://www.pharmac.govt.nz/news/consultation-2020-08-11-calcineurin-inhibitor/"" target=""_blank"">Consultation letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2020', 'fs': 'Aug 2020', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtzUAG'}, 'Id': 'a0P2P000004DKtzUAG', 'Event_Date__c': '2020-08-11', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://www.pharmac.govt.nz/news/consultation-2020-08-11-calcineurin-inhibitor/"" target=""_blank"">Consultation letter</a></p>', 'Formatted_Date__c': 'Aug 2020', 'Status_History__c': 'a132P000000C9YJQA0'}, 'change': None}]",Nov 2012,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': 'The consultation document proposed that pimecrolimus not be listed in Section H at this time, but noted that this would not prevent it from being considered for inclusion at a later date.', 'fs': 'The consultation document proposed that pimecrolimus not be listed in Section H at this time, but noted that this would not prevent it from being considered for inclusion at a later date.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/consultation-2012-11-19-pharmaceuticals-hospital-community.pdf "" target=""_blank"">Consultation letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/consultation-2012-11-19-pharmaceuticals-hospital-community.pdf "" target=""_blank"">Consultation letter</a>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2012', 'fs': 'Dec 2012', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKtpUAG'}, 'Id': 'a0P2P000004DKtpUAG', 'Event_Date__c': '2012-12-21', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/consultation-2012-11-19-pharmaceuticals-hospital-community.pdf "" target=""_blank"">Consultation letter</a>', 'Summary__c': 'The consultation document proposed that pimecrolimus not be listed in Section H at this time, but noted that this would not prevent it from being considered for inclusion at a later date.', 'Formatted_Date__c': 'Dec 2012', 'Status_History__c': 'a132P000000AqH8QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2020', 'fs': 'Aug 2020', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKu0UAG'}, 'Id': 'a0P2P000004DKu0UAG', 'Event_Date__c': '2020-08-25', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Aug 2020', 'Status_History__c': 'a132P000000C9YTQA0'}, 'change': None}]",Dec 2012,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://www.pharmac.govt.nz/news/notification-2020-08-31-tender/"" target=""_blank"">Notification letter</a></p>', 'fs': '<p><a href=""https://www.pharmac.govt.nz/news/notification-2020-08-31-tender/"" target=""_blank"">Notification letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2020', 'fs': 'Aug 2020', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000004DKu1UAG'}, 'Id': 'a0P2P000004DKu1UAG', 'Event_Date__c': '2020-08-31', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://www.pharmac.govt.nz/news/notification-2020-08-31-tender/"" target=""_blank"">Notification letter</a></p>', 'Formatted_Date__c': 'Aug 2020', 'Status_History__c': 'a132P000000C9YYQA0'}, 'change': None}]",Aug 2020,False,True
